elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q26752380-04026A50-B8DA-4824-BFAA-D21737EC6086
Q26752380-04026A50-B8DA-4824-BFAA-D21737EC6086
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26752380-04026A50-B8DA-4824-BFAA-D21737EC6086
Notch Signaling in Neuroendocrine Tumors
P2860
Q26752380-04026A50-B8DA-4824-BFAA-D21737EC6086
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26752380-04026A50-B8DA-4824-BFAA-D21737EC6086
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
fb85ab2fed51be181e94073eaeed1f644c22c661
P2860
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.